Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
Alessandra Vergori, Alessandro Cozzi Lepri, Stefania Cicalini, Giulia Matusali, Veronica Bordoni, Simone Lanini, Silvia Meschi, R Iannazzo, Valentina Mazzotta, Francesca Colavita, Ilaria Mastrorosa, Eleonora Cimini, Davide Mariotti, Lydia de Pascale, Alessandra Marani, Paola Gallì, AnnaRosa Garbuglia, Concetta Castilletti, Vincenzo Puro, Chiara Agrati, Enrico Girardi, Francesco Vaia, Andrea Antinori, HIV-VAC study group, Alessandra Amendola, Francesco Baldini, Rita Bellagamba, Aurora Bettini, Licia Bordi, Marta Camici, Rita Casetti, Sarah Costantini, Flavia Cristofanelli, Claudia D’Alessio, V D’Aquila, Alessia De Angelis, Federico De Zottis, Lydia de Pascale, Massimo Francalancia, Marisa Fusto, Roberta Gagliardini, Giulia Gramigna, Germana Grassi, Elisabetta Grilli, Susanna Grisetti, Denise Iafrate, Daniele Lapa, Patrizia Lorenzini, Alessandra Marani, Erminia Masone, Stefano Marongiu, Annalisa Mondi, Stefania Notari, Sandrine Ottou, Jessica Paulicelli, Luca Pellegrino, Carmela Pinnetti, Maria Maddalena Plazzi, Adriano Possi, Alessandra Sacchi, Eleonora Tartaglia
Abstract
Abstract In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm 3 and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm 3 (20–122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log 2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.